SKYSTAR BIO-PHARMACEUTICAL CO

SKYSTAR BIO-PHARMACEUTICAL CO insiders are currently net buyers of SKBI stock, showing bullish sentiment over the past 90 days. Executives have purchased $1.4M while selling $0, resulting in a positive net flow of $1.4M. This buying activity represents 100% of total transaction volume.

SKYSTAR BIO-PHARMACEUTICAL CO has 7 active insiders who have filed SEC Form 4 transactions in the past 90 days. John M. Gregory (Executive) leads with 6 transactions totaling $1.4M. Weibing Lu (Executive) follows with 2 transactions worth $602.0K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. SKYSTAR BIO-PHARMACEUTICAL CO's current score of 100/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $1.4M in purchases versus $0 in sales.

The most recent insider transaction occurred on May 26, 2015, when M. Gregory John (Executive) acquired 63,900 shares at $2.91 per share for $185.9K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, SKBI insider trading sentiment is currently bullish with an Alignment Score of 100/100. The net insider flow of $1.4M reflects accumulation, with 100% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like SKYSTAR BIO-PHARMACEUTICAL CO. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At SKBI, we track all Form 4 filings—currently showing 14 transactions from 7 insiders over 90 days.

A 10b5-1 plan allows SKYSTAR BIO-PHARMACEUTICAL CO executives to pre-schedule stock sales when they don't possess material non-public information. At SKBI, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at SKBI appears discretionary, making insider signals more meaningful.

You can monitor SKYSTAR BIO-PHARMACEUTICAL CO (SKBI) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 7 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. SKYSTAR BIO-PHARMACEUTICAL CO's current score of 100/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $1.4M in purchases versus $0 in sales over 90 days, resulting in a net flow of $1.4M.

SEC Form 4 filings are mandatory reports that SKYSTAR BIO-PHARMACEUTICAL CO insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At SKBI, the most common type is "A" with 8 occurrences. The most recent Form 4 was filed on May 26, 2015 by M. Gregory John.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At SKYSTAR BIO-PHARMACEUTICAL CO, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at SKBI represents discretionary decisions with more informational value.